Compare INHD & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | CLGN |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 33.8M |
| IPO Year | 2023 | N/A |
| Metric | INHD | CLGN |
|---|---|---|
| Price | $0.14 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 52.3M | 20.8K |
| Earning Date | 12-09-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,645,845.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | N/A | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 787.64 | 280.77 |
| 52 Week Low | $0.12 | $1.31 |
| 52 Week High | $19.78 | $4.98 |
| Indicator | INHD | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 20.25 | 36.52 |
| Support Level | $0.14 | $1.77 |
| Resistance Level | $0.16 | $1.93 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 0.70 | 10.20 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.